GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » DaVita Inc (BSP:DVAI34) » Definitions » Tax Expense

DaVita (BSP:DVAI34) Tax Expense : R$1,431 Mil (TTM As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is DaVita Tax Expense?

DaVita's tax expense for the months ended in Sep. 2024 was R$430 Mil. Its tax expense for the trailing twelve months (TTM) ended in Sep. 2024 was R$1,431 Mil.


DaVita Tax Expense Historical Data

The historical data trend for DaVita's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DaVita Tax Expense Chart

DaVita Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,147.73 1,615.09 1,734.54 1,039.05 1,078.52

DaVita Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 340.02 286.61 327.70 386.12 430.14

DaVita Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was R$1,431 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DaVita  (BSP:DVAI34) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


DaVita Tax Expense Related Terms

Thank you for viewing the detailed overview of DaVita's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


DaVita Business Description

Traded in Other Exchanges
Address
2000 16th Street, Denver, CO, USA, 80202
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the us, and treats about 250,000 patients globally each year. Government payers dominate us dialysis reimbursement. DaVita receives about two thirds of us sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of the us patients treated, they represent nearly all of the profits generated by DaVita in the us dialysis business.

DaVita Headlines

No Headlines